FDA Determines Regulatory Review Period for INVEGA Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for INVEGA, a human drug product, as required by law, following a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.